HRP20220605T1 - Postupak za proizvodnju stabilne emulzije za isporuku peptida - Google Patents
Postupak za proizvodnju stabilne emulzije za isporuku peptida Download PDFInfo
- Publication number
- HRP20220605T1 HRP20220605T1 HRP20220605TT HRP20220605T HRP20220605T1 HR P20220605 T1 HRP20220605 T1 HR P20220605T1 HR P20220605T T HRP20220605T T HR P20220605TT HR P20220605 T HRP20220605 T HR P20220605T HR P20220605 T1 HRP20220605 T1 HR P20220605T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- peptide
- suspension
- solution
- oil
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 34
- 238000000034 method Methods 0.000 title claims 14
- 239000000839 emulsion Substances 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000000725 suspension Substances 0.000 claims 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 239000012752 auxiliary agent Substances 0.000 claims 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 235000019198 oils Nutrition 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 239000005662 Paraffin oil Substances 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 229940042472 mineral oil Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 229940032094 squalane Drugs 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Preparation And Processing Of Foods (AREA)
- Colloid Chemistry (AREA)
Claims (11)
1. Postupak za proizvodnju peptidne emulzije spremne za uporabu u industrijskoj skali, koji sadrži korak emulgiranja suspenzije od najmanje dva peptida u uvjetima niskog smicanja, pri brzini rotacije između 100 i 1000 o/min, tijekom 2 do 20 minuta, s najmanje jednim pomoćnim sredstvom, pri čemu postupak ne sadrži nijedan korak miješanja pri velikoj brzini, posebno iznad 7000 o/min.
2. Postupak prema zahtjevu 1, naznačen time što peptidi sadrže najmanje jedan topivi peptid i najmanje jedan netopivi peptid.
3. Postupak prema zahtjevu 1 ili 2, naznačen time što su peptidi odabrani iz grupe koju čine: peptid KVFGSLAFV (SEQ ID NO:7), peptid YLSGADLNL (SEQ ID NO:8), peptid KLBPVQLWV sa B koji označava α-aminoizobutirnu kiselinu (SEQ ID NO:6), peptid SMPPPGTRV (SEQ ID NO:5), peptid IMIGHLVGV (SEQ ID NO:9), peptid LLTFWNPPV (SEQ ID NO:4), peptid RLLQETELV (SEQ ID NO:2), peptid aKXVAAWTLKAAa sa X respektivno označavajući cikloheksilalanin i d-alanin (SEQ ID NO:1), peptid YLQLVFGIEV (SEQ ID NO:3) i peptid KVAEIVHFL (SEQ ID NO: 10).
4. Postupak prema zahtjevu 3, naznačen time što suspenzija sadrži kombinaciju peptida KVFGSLAFV (SEQ ID NO:7), peptida YLSGADLNL (SEQ ID NO:8), peptida KLBPVQLWV (SEQ ID NO:6), peptid SMPPPGTRV (SEQ ID NO:5), peptid IMIGHLVGV (SEQ ID NO:9), peptid LLTFWNPPV (SEQ ID NO:4), peptid RLLQETELV (SEQ ID NO:2), peptid aKXVAAWTLKAAa sa X i respektivno označavajući cikloheksilalanin i d-alanin (SEQ ID NO:1), peptid YLQLVFGIEV (SEQ ID NO:3) i peptid KVAEIVHFL (SEQ ID NO:10).
5. Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time što se pomoćno sredstvo sastoji od mješavine ugljikovodičnog ulja s emulgatorom voda u ulju.
6. Postupak prema zahtjevu 5, naznačen time što je ugljikovodično ulje odabrano između parafinskog ulja, biljnog ulja, skvalena, skvalana ili mineralnog ulja i emulgator voda u ulju je odabran između manid mono-oleata i sorbitan mono-oleata.
7. Postupak prema zahtjevu 5 ili 6, naznačen time što se težinski omjer pomoćnog sredstva prema suspenziji peptida kreće od 10:1 do 1:10, poželjno od 5:1 do 1:5 i više poželjnije od 2:1 do 1:2 i još poželjnije je 1:1.
8. Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time što se cijeli ili dio koraka miješanja izvodi u inertnoj atmosferi, poželjno pod dušikom.
9. Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je volumen emulzije veći od 5L, poželjno veći ili jednak 10L.
10. Postupak prema bilo kojem od zahtjeva 3 do 8, naznačen time što se suspenzija peptida priprema postupkom koji sadrži:
a) pripremu najmanje tri različite otopine A, B i C, pri čemu:
• otopina A koja je kiseli vodeni medij i sadrži peptid aKXVAAWTLKAAa (SEQ ID NO:1) sa X i respektivno označavajući cikloheksilalanin i d-alanin (SEQ ID NO:1),
• otopina B je bazični vodeni medij s pH između 12.5 i 12.9 prije dodavanja bilo kojeg peptida u njega i otopina B koja sadrži peptid YLSGADLNL (SEQ ID NO:8),
• otopina C je DMSO i sadrži peptid KVFGSLAFV (SEQ ID NO:7), i
• otopine A i/ili B nadalje sadrže najmanje tri dodatna peptida odabrana između: KLBPVQLWV sa B koji označava α-aminoizobutirnu kiselinu (SEQ ID NO:6), SMPPPGTRV (SEQ ID NO:5), IMIGHLVGV (SEQ ID NO:9), LLTFWNPPV (SEQ ID NO:4), KVAEIVHFL (SEQ ID NO:10), RLLQETELV (SEQ ID NO:2) i YLQLVFGIEV (SEQ ID NO:3);
b) miješanje navedenih otopina tako da se dobije suspenzija, i
c) podešavanje pH navedene suspenzije na oko 7.
11. Postupak prema zahtjevu 10, naznačen time što otopina A sadrži aKXVAAWTLKAAa (SEQ ID NO:1), SMPPPGTRV (SEQ ID NO:5), IMIGHLVGV (SEQ ID NO:9) i KVAEIVHFL (SEQ ID NO:10) i otopina B sadrži YLSGADLNL (SEQ ID NO:8), KLBPVQLWV (SEQ ID NO:6), LLTFWNPPV (SEQ ID NO:4), RLLQETELV (SEQ ID NO:2) i YLQLVFGIEV (SEQ ID NO:3).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305079 | 2017-01-25 | ||
| EP18710760.2A EP3573600B1 (en) | 2017-01-25 | 2018-01-24 | Method for manufacturing a stable emulsion for peptide delivery |
| PCT/EP2018/051647 WO2018138110A1 (en) | 2017-01-25 | 2018-01-24 | Method for manufacturing a stable emulsion for peptide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220605T1 true HRP20220605T1 (hr) | 2022-07-08 |
Family
ID=57965869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220605TT HRP20220605T1 (hr) | 2017-01-25 | 2018-01-24 | Postupak za proizvodnju stabilne emulzije za isporuku peptida |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11325959B2 (hr) |
| EP (2) | EP3573600B1 (hr) |
| JP (1) | JP7140778B2 (hr) |
| KR (1) | KR102577036B1 (hr) |
| CN (2) | CN110191703B (hr) |
| AR (1) | AR113209A1 (hr) |
| AU (1) | AU2018213890B2 (hr) |
| BR (1) | BR112019014917A2 (hr) |
| CA (1) | CA3047492C (hr) |
| DK (1) | DK3573600T3 (hr) |
| ES (1) | ES2913268T3 (hr) |
| HR (1) | HRP20220605T1 (hr) |
| HU (1) | HUE058717T2 (hr) |
| IL (1) | IL267237B2 (hr) |
| LT (1) | LT3573600T (hr) |
| MX (1) | MX2019008878A (hr) |
| PL (1) | PL3573600T3 (hr) |
| PT (1) | PT3573600T (hr) |
| RS (1) | RS63259B1 (hr) |
| SI (1) | SI3573600T1 (hr) |
| TW (1) | TWI793099B (hr) |
| WO (1) | WO2018138110A1 (hr) |
| ZA (1) | ZA201905487B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220605T1 (hr) | 2017-01-25 | 2022-07-08 | Ose Immunotherapeutics | Postupak za proizvodnju stabilne emulzije za isporuku peptida |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1620456T3 (pl) | 2003-04-18 | 2014-06-30 | Ose Pharma Int Sa | Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje |
| CN102850433B (zh) | 2006-10-17 | 2016-03-02 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
| TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| JP5493076B2 (ja) | 2007-08-20 | 2014-05-14 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ１ペプチド及びこれを含む薬剤 |
| US20110104101A1 (en) | 2008-03-06 | 2011-05-05 | University Of Medicine And Dentistry Of New Jersey | Immunotherapy for Unresectable Pancreatic Cancer |
| RU2532105C2 (ru) | 2008-10-22 | 2014-10-27 | Онкотерапи Сайенс, Инк. | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины |
| TWI507204B (zh) | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| EP2292258A1 (en) | 2009-08-18 | 2011-03-09 | Pevion Biotech Ltd. | Multiepitope vaccine for Her2/neu-associated cancers |
| TW201124530A (en) | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| SG10201501857YA (en) | 2010-03-11 | 2015-05-28 | Oncotherapy Science Inc | Hjurp Peptides And Vaccines Including The Same |
| TW201216982A (en) | 2010-10-21 | 2012-05-01 | Oncotherapy Science Inc | WDHD1 peptides and vaccines including the same |
| AU2011319353A1 (en) | 2010-10-21 | 2013-06-13 | Oncotherapy Science, Inc. | C18orf54 peptides and vaccines including the same |
| UA110119C2 (xx) | 2010-12-02 | 2015-11-25 | Пептиди tomm34 та вакцини, що їх містять | |
| TW201302800A (zh) | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| CA2842887C (en) | 2011-08-12 | 2021-01-19 | Oncotherapy Science, Inc. | Mphosph1 peptides and vaccines including the same |
| MX355759B (es) | 2011-10-28 | 2018-04-27 | Oncotherapy Science Inc | Peptidos topk y vacunas que incluyen los mismos. |
| SI2785375T1 (sl) | 2011-11-28 | 2020-11-30 | Merck Patent Gmbh | Protitelesa proti PD-L1 in uporabe le-teh |
| MX362912B (es) | 2012-09-11 | 2019-02-22 | Oncotherapy Science Inc | Péptidos ube2t y vacunas que incluyen los mismos. |
| WO2014047085A2 (en) | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
| WO2014127276A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Ovarian cancer vaccines and vaccination methods |
| WO2014136453A1 (en) | 2013-03-08 | 2014-09-12 | Oncotherapy Science, Inc. | C12orf48 PEPTIDES AND VACCINES CONTAINING THE SAME |
| WO2014141652A1 (en) | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| WO2014162962A1 (ja) | 2013-04-01 | 2014-10-09 | 学校法人 久留米大学 | 腫瘍抗原ペプチド |
| GB2530236A (en) | 2014-04-11 | 2016-03-23 | Univ Nottingham Trent | PAP Peptide analogues |
| WO2015160928A2 (en) | 2014-04-15 | 2015-10-22 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| EP2944652A1 (en) | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| KR102043725B1 (ko) * | 2014-11-06 | 2019-11-13 | 오제 이뮈노테라프틱스 | 뇌 전이 치료를 위한 치료용 다중 펩타이드 t 특이적 면역 요법 |
| BR112017027653A2 (pt) * | 2015-06-29 | 2018-08-28 | Ose Immunotherapeutics | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos |
| HRP20220605T1 (hr) | 2017-01-25 | 2022-07-08 | Ose Immunotherapeutics | Postupak za proizvodnju stabilne emulzije za isporuku peptida |
| BR112020010656A2 (pt) | 2017-11-27 | 2020-11-10 | Ose Immunotherapeutics | tratamento aprimorado de câncer |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| US20220025050A1 (en) | 2018-12-21 | 2022-01-27 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| JP2022514698A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗ｐｄ－１／ｓｉｒｐａ分子 |
| CN116063513A (zh) | 2018-12-21 | 2023-05-05 | Ose免疫疗法公司 | 人源化的抗人pd-1抗体 |
-
2018
- 2018-01-24 HR HRP20220605TT patent/HRP20220605T1/hr unknown
- 2018-01-24 AU AU2018213890A patent/AU2018213890B2/en active Active
- 2018-01-24 SI SI201830646T patent/SI3573600T1/sl unknown
- 2018-01-24 US US16/477,534 patent/US11325959B2/en active Active
- 2018-01-24 BR BR112019014917-1A patent/BR112019014917A2/pt active Search and Examination
- 2018-01-24 EP EP18710760.2A patent/EP3573600B1/en active Active
- 2018-01-24 CA CA3047492A patent/CA3047492C/en active Active
- 2018-01-24 EP EP22153774.9A patent/EP4029494A1/en active Pending
- 2018-01-24 WO PCT/EP2018/051647 patent/WO2018138110A1/en unknown
- 2018-01-24 PL PL18710760T patent/PL3573600T3/pl unknown
- 2018-01-24 MX MX2019008878A patent/MX2019008878A/es unknown
- 2018-01-24 JP JP2019560481A patent/JP7140778B2/ja active Active
- 2018-01-24 DK DK18710760.2T patent/DK3573600T3/da active
- 2018-01-24 KR KR1020197024340A patent/KR102577036B1/ko active IP Right Grant
- 2018-01-24 PT PT187107602T patent/PT3573600T/pt unknown
- 2018-01-24 ES ES18710760T patent/ES2913268T3/es active Active
- 2018-01-24 LT LTEPPCT/EP2018/051647T patent/LT3573600T/lt unknown
- 2018-01-24 CN CN201880007527.3A patent/CN110191703B/zh active Active
- 2018-01-24 RS RS20220413A patent/RS63259B1/sr unknown
- 2018-01-24 HU HUE18710760A patent/HUE058717T2/hu unknown
- 2018-01-24 CN CN202210293478.2A patent/CN114917189B/zh active Active
- 2018-01-24 IL IL267237A patent/IL267237B2/en unknown
- 2018-01-25 AR ARP180100167A patent/AR113209A1/es unknown
- 2018-01-25 TW TW107102651A patent/TWI793099B/zh active
-
2019
- 2019-08-20 ZA ZA2019/05487A patent/ZA201905487B/en unknown
-
2022
- 2022-05-04 US US17/736,113 patent/US11981713B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiong et al. | Emulsion stability and dilatational viscoelasticity of ovalbumin/chitosan complexes at the oil-in-water interface | |
| Xu et al. | Novel pickering high internal phase emulsion gels stabilized solely by soy β-conglycinin | |
| Bai et al. | Formation and stabilization of nanoemulsions using biosurfactants: Rhamnolipids | |
| Ruiz et al. | Effect of extraction pH on heat-induced aggregation, gelation and microstructure of protein isolate from quinoa (Chenopodium quinoa Willd) | |
| Chen et al. | The effect of adding NaCl on thermal aggregation and gelation of soy protein isolate | |
| Zhang et al. | Improvement of emulsifying properties of oat protein isolate–dextran conjugates by glycation | |
| Yang et al. | Rethinking plant protein extraction: Albumin—From side stream to an excellent foaming ingredient | |
| Niu et al. | Synergistic effects of ovalbumin/gum arabic complexes on the stability of emulsions exposed to environmental stress | |
| Turgeon et al. | Protein+ polysaccharide coacervates and complexes: from scientific background to their application as functional ingredients in food products | |
| US8431620B2 (en) | Process for the preparation of water-in-oil and oil-in-water nanoemulsions | |
| Ray et al. | Stabilization of oil-in-water emulsions using mixtures of denatured soy whey proteins and soluble soybean polysaccharides | |
| Tchuenbou-Magaia et al. | Hydrophobins stabilised air-filled emulsions for the food industry | |
| CN104371695B (zh) | 应用于页岩气工厂化压裂开采的滑溜水的制备方法 | |
| Mohammadian et al. | Gelation of oil-in-water emulsions stabilized by heat-denatured and nanofibrillated whey proteins through ion bridging or citric acid-mediated cross-linking | |
| MX2017014523A (es) | Latex de agua en aceite invertibles y sus metodos de uso. | |
| RU2017127287A (ru) | Съедобные грибы | |
| WO2008006713A3 (en) | Improvements relating to anti-parasitic compositions | |
| NO20044739L (no) | Polysakkaridkapsler og fremgangsmater for fremstilling derav | |
| HRP20220605T1 (hr) | Postupak za proizvodnju stabilne emulzije za isporuku peptida | |
| CN102575244A (zh) | 抗生物素蛋白与生物素衍生物的解离方法以及解离剂 | |
| WO2006005731A3 (en) | Novel inverse latex with a low content of monomer comprising a strong acid functional group and use in the manufacture of topical compositions | |
| EA201001439A1 (ru) | Трехфазная эмульсия (варианты), способ ее приготовления и нанесения | |
| CN103120158A (zh) | 一种用于悬浮剂的复配增效剂 | |
| CN102970976A (zh) | 水包油乳液的制备方法 | |
| NO20101567L (no) | Gjensidig losemiddelloselige og/eller alkoholblandingsloselige partikler for viskoelastiske overflateaktive fluider |